v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information

Note 6 – Segment Information

 

The Company operates and manages its business as one reportable and operating as a clinical stage biopharmaceutical company focused on the development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE®), and Tetra-specific Killer Engager (Dual Targeting TriKE®) platforms. The measure of segment assets is reported on the balance sheet as total assets. 

 

The Company’s CODM reviews financial information presented and decides how to allocate resources based on net income (loss). Net income (loss) is used for evaluating financial performance.

 

Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:

 

   2026   2025   2026   2025 
  

Three Months Ended

June 30,

  

Six Months Ended

June 30,

 
   2026   2025   2026   2025 
Research and development  $1,055,000   $363,000   $1,468,000   $1,462,000 
Salaries   410,000    351,000    771,000    632,000 
Insurance   43,000    61,000    83,000    121,000 
Stock-based compensation   46,000    4,000    92,000    7,000 
Operating expenses   2,958,000    734,000    4,946,000    1,223,000 
Loss on initial recognition of Greenshoe Rights liability   —    28,736,000    —    28,736,000 
Other expense (income)   6,000    (80,000)   (9,000)   (1,236,000)
Net loss  $4,518,000   $30,169,000   $7,351,000   $30,945,000